All stock lists
Unlock the score
Quanterix Corp (NASDAQ:QTRX)
US · Delayed Price · Currency is USD
Healthcare · Medical - Devices
2.85
Insider Score
/ 100
QTRX Insider Score
Quanterix Corp has a live Insider Score.
Scored on 2 qualifying trades from 1 insider in the last 90 days.
QTRX analyst forecast
QTRX analyst consensus
Hold2 ratings
Buy 0 Hold 2 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
QTRX 12-month price target
$3.00+5.6% upsideaverage of 1 firm
$3.00High
$3.00Low
Best analysts covering QTRX
No firm covering QTRX has enough calls with a finished 1Y holding period to rank yet.
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
QTRX analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | TD Cowen | Hold | — | — | Reiterated | 2026-10-13 |
| Canaccord Genuity | Hold | $3.00 | +15.8% | Reiterated | 2026-08-17 | |
| — | TD Cowen | Hold | — | — | Reiterated | 2026-08-11 |
| — | TD Cowen | Hold | — | — | Reiterated | 2026-05-07 |
| — | Canaccord Genuity | Hold | — | — | Reiterated | 2026-04-20 |
| — | Canaccord Genuity | Hold | — | — | Reiterated | 2025-12-22 |
| — | Canaccord Genuity | Hold | — | — | Downgraded | 2025-08-11 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2025-05-13 |
| — | Leerink Partners | Market Perform | — | — | Downgraded | 2025-04-30 |
| Scotiabank | Sector Outperform | $18.00 | +156.4% | Reiterated | 2025-03-25 | |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2025-03-18 |
| — | TD Cowen | Hold | — | — | Reiterated | 2024-11-13 |
| — | Scotiabank | Sector Outperform | — | — | Reiterated | 2024-08-12 |
| — | TD Cowen | Hold | — | — | Reiterated | 2024-08-09 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2024-07-09 |
| Scotiabank | — | $32.00 | +73.0% | — | 2024-06-11 | |
| Canaccord Genuity | — | $25.00 | +51.4% | — | 2024-05-08 | |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2024-04-29 |
| — | Scotiabank | Sector Outperform | — | — | Reiterated | 2024-03-04 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2023-09-28 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2023-09-27 |
| — | Canaccord Genuity | Buy | — | — | Upgraded | 2023-09-25 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2023-08-09 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2023-05-24 |
| — | Goldman Sachs | Buy | — | — | Upgraded | 2023-05-23 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2022-11-10 |
| — | SVB Leerink | Market Perform | — | — | Reiterated | 2022-11-09 |
| — | Canaccord Genuity | Hold | — | — | Downgraded | 2022-08-15 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2022-08-10 |
| — | Cowen & Co. | Market Perform | — | — | Downgraded | 2022-08-09 |
| — | SVB Leerink | Market Perform | — | — | Downgraded | 2022-08-09 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2022-07-14 |
| — | SVB Leerink | Outperform | — | — | Reiterated | 2022-05-11 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2022-05-11 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2022-04-13 |
| — | Goldman Sachs | Neutral | — | — | Upgraded | 2022-03-02 |
| — | SVB Leerink | Outperform | — | — | Reiterated | 2022-03-02 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2022-03-02 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2021-08-05 |
| — | Goldman Sachs | Sell | — | — | Reiterated | 2021-06-04 |
| — | SVB Leerink | Outperform | — | — | Reiterated | 2021-05-06 |
| — | SVB Leerink | Outperform | — | — | Reiterated | 2021-03-03 |
| — | SVB Leerink | Outperform | — | — | Reiterated | 2021-01-27 |
| — | SVB Leerink | Outperform | — | — | Reiterated | 2020-11-06 |
| — | SVB Leerink | Outperform | — | — | Reiterated | 2020-10-19 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2020-10-06 |
| — | SVB Leerink | Outperform | — | — | Reiterated | 2020-08-05 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2018-10-10 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2018-01-02 |
| — | Leerink Swann | Outperform | — | — | Reiterated | 2018-01-02 |
| — | BTIG Research | Buy | — | — | Reiterated | 2018-01-02 |
| — | Cowen & Co. | Outperform | — | — | Reiterated | 2018-01-02 |
QTRX earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-02 | -0.27 | -0.38 | $38.2M | $43.9M |
| 2026-05-06 | -0.31 | -0.39 | $36.8M | $36.4M |
| 2026-08-10 | -0.41 | -1.04 | $37.5M | $32.9M |
| 2026-11-09 | -0.42 | 0.00 | $33.9M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.